| |
Group 1 n = 10 (15–39 years, Nonimmunocompromised)
|
Group 2 n = 48 (40–64 years Nonimmunocompromised)
|
Group 3 n = 116 (> = 65 years, Nonimmunocompromised)
|
Group 4 n = 107 (> = 15 years Immunocompromised)
|
|---|
|
Variable
|
n/Na (%)
|
n/Na (%)
|
n/Na (%)
|
n/Na (%)
|
|---|
|
Female
|
3/10 (30)
|
10/48 (21)
|
46/116 (40)
|
44/107 (41)
|
|
BMI
|
|
Normal or Healthy Weight (18.5 – 24.9)
|
5/7 (71)
|
24/42 (57)
|
57/95 (60)
|
47/97 (48)
|
|
Overweight (25.0 and Above)
|
0/7 (0)
|
11/42 (26)
|
12/95 (13)
|
17/97 (18)
|
|
Underweight (Below 18.5)
|
2/7 (29)
|
7/42 (17)
|
26/95 (27)
|
33/97 (34)
|
|
Smoking history
|
5/9 (56)
|
26/44 (59)
|
49/100 (49)
|
48/95 (51)
|
|
Alcohol abuse
|
2/9 (22)
|
13/43 (30)
|
13/103 (13)
|
11/95 (12)
|
|
Preceding influenza
|
0/4 (0)
|
2/34 (6)
|
8/83 (10)
|
1/66 (2)
|
|
Vaccination history of PPSV23
|
0/8 (0)
|
1/40 (3)
|
6/91 (7)
|
9/85 (11)
|
|
Comorbidities
|
1/10 (10)
|
25/48 (52)
|
69/116 (59)
|
107/107 (100)
|
|
Clinical presentation
|
|
Bacteremia without any focus
|
1/10 (10)
|
4/48 (8)
|
12/116 (10)
|
29/107 (27)
|
|
Meningitis
|
3/10 (30)
|
9/48 (19)
|
18/116 (16)
|
14/107 (13)
|
|
Bacteremic pneumonia
|
6/10 (60)
|
27/48 (56)
|
80/116 (69)
|
54/107 (50)
|
|
Othersb
|
0/10 (10)
|
8/48 (17)
|
6/116 (5)
|
10/107 (9)
|
|
Outcomec
|
|
Fatal
|
0/10 (0)
|
6/48 (13)
|
18/116 (16)
|
31/107 (29)
|
|
Serotype
|
|
PCV13 type
|
4/10 (40)
|
27/48 (56)
|
65/116 (56)
|
34/107 (32)
|
|
PPSV23 type
|
7/10 (70)
|
38/48 (79)
|
85/116 (73)
|
55/107 (51)
|
- BMI Body mass index, PPSV23 23-valent pneumococcal polysaccharide vaccine
- a Number of available answers
- b Others included bacteremic arthritis, bacteremic cellulitis, bacteremic spondylitis bacteremic cholangitis, bacteremic empyema, infected aortic aneurysm and infective endocarditis
- c The case fatality was defined as reporting of death by the case-reporting form at the time of reporting
